Beijing Luzhu Biotechnology Future Growth
Future criteria checks 2/6
Beijing Luzhu Biotechnology is forecast to grow earnings and revenue by 36.3% and 54.7% per annum respectively. EPS is expected to decline by 0.6% per annum. Return on equity is forecast to be -1464.5% in 3 years.
Key information
36.3%
Earnings growth rate
-0.6%
EPS growth rate
Biotechs earnings growth | 34.9% |
Revenue growth rate | 54.7% |
Future return on equity | -1,464.5% |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 310 | -256 | -231 | -176 | 2 |
12/31/2025 | 100 | -336 | -243 | -200 | 2 |
12/31/2024 | 1 | -326 | -268 | -207 | 2 |
12/31/2023 | N/A | -249 | -276 | -190 | N/A |
9/30/2023 | N/A | -201 | -307 | -153 | N/A |
6/30/2023 | N/A | -152 | -339 | -117 | N/A |
3/31/2023 | N/A | -439 | -314 | -97 | N/A |
12/31/2022 | N/A | -725 | -289 | -77 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2480 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2480 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2480 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2480's revenue (54.7% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2480's revenue (54.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2480 is forecast to be unprofitable in 3 years.